Hot View Biotech (688068.SH): SGC001 innovative drug reports phase Ib clinical data in AHA in the form of a poster

Zhitongcaijing · 1d ago

Zhitong Finance App News, Hotjing Biotech (688068.SH) issued an announcement. Recently, the company's holding subsidiary, Beijing Shunjing Biomedical Technology Co., Ltd. (“Shunjing Pharmaceutical”), reported the SGC001 injection phase iB clinical study data in the form of a poster at the American Heart Association Scientific Annual Meeting (AHA).

SGC001 is an emergency monoclonal antibody drug developed by the R&D team of Shunjing Pharmaceutical and the Beijing Institute of Cardiopulmonary Vascular Diseases of Beijing Anzhen Hospital affiliated with Capital Medical University. It is suitable for emergency treatment of patients with acute myocardial infarction (AMI) (the first indication is “anterior wall ST segment elevation myocardial infarction”). Previously, for AMI disease, no relevant antibody drugs have entered the clinical research stage and approved for marketing.

The phase Ib clinical study presented at the AHA conference initially verified the good safety tolerability of the drug, observed positive exploratory efficacy signals, and provided strong support for subsequent research and development.